Results 81 to 90 of about 22,351 (243)

PEPITEM Regulates the Synovial Microenvironment During Immune‐Mediated Inflammatory Arthritis to Limit Disease

Arthritis &Rheumatology, EarlyView.
Objective Here we investigate the status of the adiponectin–PEPITEM pathway in early, treatment naive rheumatoid arthritis (RA) and psoriatic arthritis (PsA) and the therapeutic efficacy of PEPITEM administration in preclinical models. Methods Peripheral blood was isolated from patients with clinical suspect arthralgia and suspected inflammatory ...
Mussarat Wahid, Samuel Kemble, Oladimeji Abudu, Anella Saviano, Christopher Mahony, Jonathan W. Lewis, Thomas A. Nicholson, Anna Schettino, Noemi Marigliano, Kathryn Frost, Jenefa Begum, Alyssa M. Urbanowski, Marion Limo, Rakesh Jha, Sandra Martinez Jarquin, Laleh Pezhman, Abbie E. A. Degan, Amy E. Anderson, Charlotte G. Smith, Armaiti Batki, Holly Adams, Francesco Caso, Raffaele Scarpa, Iain McInnes, Stefan Siebert, Arthur G. Pratt, Andrew Filer, Karim Raza, Adam P. Croft, Myriam Chimen, Felicity de Cogan, G. Ed Rainger, Asif J. Iqbal, Francesco Maione, Helen M. McGettrick   +34 more
wiley   +1 more source

Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner. [PDF]

, 2020
The brain-derived neurotrophic factor (BDNF) plays crucial roles in both the developing and mature brain. Moreover, alterations in BDNF levels are correlated with the cognitive impairment observed in several neurological diseases.
Nicoletta Landsberger, Landsberger, Nicoletta, Marta Zagrebelsky, Frasca, Angelisa, Abhisarika Patnaik, Spiombi, Eleonora, Zagrebelsky, Marta, Eleonora Spiombi, Patnaik, Abhisarika, Korte, Martin, Angelisa Frasca, Martin Korte   +11 more
core   +3 more sources

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod

Frontiers in Neurology, 2019
Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor and is widely used for relapsing-remitting multiple sclerosis (MS).
Ryoko Fukai, Keita Takahashi, Hiroyuki Abe, Yuichi Higashiyama, Hiroshi Doi, Hideyuki Takeuchi, Fumiaki Tanaka   +6 more
doaj   +1 more source

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

Journal of Neuroinflammation, 2022
Background The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine.
Celia Camacho-Toledano, Isabel Machín-Díaz, Leticia Calahorra, María Cabañas-Cotillas, David Otaegui, Tamara Castillo-Triviño, Luisa María Villar, Lucienne Costa-Frossard, Manuel Comabella, Luciana Midaglia, José Manuel García-Domínguez, Jennifer García-Arocha, María Cristina Ortega, Diego Clemente   +13 more
doaj   +1 more source

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Brain Sciences, 2022
Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy ...
Helmut Butzkueven, Paul S. Giacomini, Stanley Cohan, Tjalf Ziemssen, Daniel Sienkiewicz, Ying Zhang, Yvonne Geissbühler, Diego Silva, Davorka Tomic, Harald Kropshofer, Maria Trojano   +10 more
doaj   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod

Drug Design, Development and Therapy, 2014
Jorge Correale,1 Erwin Chiquete,2 Snezana Milojevic,3 Nadina Frider,3 Imre Bajusz31Raúl Carrea Institute for Neurological Research, Foundation for the Fight against Infant Neurological Illnesses, Buenos Aires, Argentina; 2Department of Neurology ...
Correale J, Chiquete E, Milojevic S, Frider N, Bajusz I   +4 more
doaj  

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis

Journal of Investigative Medicine High Impact Case Reports, 2015
A man with relapsing multiple sclerosis, treated with fingolimod 0.5 mg/d for 15 months, developed acute lymphoblastic leukemia and died 4 months after immune ablation and bone marrow allograft, from graft versus host disease.
Stanley Cohan MD, PhD, John Godwin MD, Leah Gaedeke FNP   +2 more
doaj   +1 more source

Exploring Healthcare Continuity in Pediatric‐Onset Multiple Sclerosis in the United States

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Little is known about shifting from pediatric to adult‐focused multiple sclerosis (MS) care. This study aims to explore transition of care and follow‐up in the US pediatric‐onset MS (POMS) population. Methods Surveys were distributed to 10 sites in the US Network of Pediatric MS Centers (US NPMSC) about transition‐of‐care practices ...
Aaron W. Abrams, Michael Waltz, Jonathan Race, T. Charles Casper, Claudia Gambrah‐Lyles, Kimberly O'Neill, Akash Virupakshaiah, Kristen S. Fisher, Melissa A. Wright, Kelsey E. Poisson, Eva‐Chava M. Bernfeld, Gregory Aaen, Leslie A. Benson, Tanuja Chitnis, Carla Francisco, Grace Y. Gombolay, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, John Rose, US Network of Pediatric MS Centers   +31 more
wiley   +1 more source

Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis

, 2017
Charlotte Druart, Souraya El Sankari, Vincent van Pesch Neurology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium Abstract: With a growing number of disease-modifying therapies becoming ...
Van Pesch, Vincent, Druart C, van Pesch V, Souraya El Sankari, El Sankari S, Vincent van Pesch, Druart, Charlotte, Charlotte Druart, El Sankari, Souraya   +8 more
core   +1 more source